HPV vaccine recommendations by age: A survey of providers in federally qualified health centers.

Paige Lake, Lindsay Fuzzell, Naomi C Brownstein, Holly B Fontenot, Alexandra Michel, McKenzie McIntyre, Ashley Whitmer, Sarah L Rossi, Rebecca B Perkins, Susan T Vadaparampil
Author Information
  1. Paige Lake: Health Outcomes and Behavior, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  2. Lindsay Fuzzell: Health Outcomes and Behavior, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  3. Naomi C Brownstein: Office of Community Outreach, Engagement, and Equity, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  4. Holly B Fontenot: Nancy Atmospera-Walch School of Nursing, University of Hawaii at Manoa, Honolulu, HI, USA.
  5. Alexandra Michel: Nancy Atmospera-Walch School of Nursing, University of Hawaii at Manoa, Honolulu, HI, USA.
  6. McKenzie McIntyre: Health Outcomes and Behavior, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  7. Ashley Whitmer: Health Outcomes and Behavior, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  8. Sarah L Rossi: Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston University, Boston, MA, USA.
  9. Rebecca B Perkins: Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston University, Boston, MA, USA. ORCID
  10. Susan T Vadaparampil: Health Outcomes and Behavior, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

Abstract

Clinician recommendation remains a critical factor in improving HPV vaccine uptake. Clinicians practicing in federally qualified health centers were surveyed between October 2021 and July 2022. Clinicians were asked how they recommended HPV vaccination for patients aged 9-10, 11-12, 13-18, 19-26, and 27-45 y (strongly recommend, offer but do not recommend strongly, discuss only if the patient initiates the conversation, or recommend against). Descriptive statistics were assessed, and exact binomial logistic regression analyses were utilized to examine factors associated with HPV vaccination recommendation in 9-10-y-old patients. Respondents (n = 148) were primarily female (85%), between the ages of 30-39 (38%), white, non-Hispanic (62%), advanced practice providers (55%), family medicine specialty (70%), and practicing in the Northeast (63%). Strong recommendations for HPV vaccination varied by age: 65% strongly recommended for ages 9-10, 94% for ages 11-12, 96% for ages 13-18, 82% for age 19-26, and 26% for ages 27-45 y. Compared to Women's Health/OBGYN specialty, family medicine clinicians were less likely to recommend HPV vaccination at ages 9-10 ( = .03). Approximately two-thirds of clinicians practicing in federally qualified health centers or safety net settings strongly recommend HPV vaccine series initiation at ages 9-10. Additional research is needed to improve recommendations in younger age groups.

Keywords

References

  1. J Natl Cancer Inst. 2015 Apr 29;107(6):djv086 [PMID: 25925419]
  2. BMC Med. 2013 Oct 22;11:227 [PMID: 24148310]
  3. Vaccine. 2016 Feb 24;34(9):1187-92 [PMID: 26812078]
  4. J Community Health. 2019 Jun;44(3):436-443 [PMID: 30661151]
  5. MMWR Morb Mortal Wkly Rep. 2011 Dec 23;60(50):1705-8 [PMID: 22189893]
  6. Pediatrics. 2020 Jul;146(1): [PMID: 32540986]
  7. CA Cancer J Clin. 2022 Nov;72(6):561-569 [PMID: 35969145]
  8. J Infect Dis. 2009 Apr 1;199(7):926-35 [PMID: 19236279]
  9. Prev Med Rep. 2022 Mar 15;27:101772 [PMID: 35321213]
  10. Hum Vaccin Immunother. 2018;14(10):2503-2509 [PMID: 29847201]
  11. J Low Genit Tract Dis. 2022 Jan 1;26(1):13-19 [PMID: 34928249]
  12. MMWR Morb Mortal Wkly Rep. 2022 Sep 02;71(35):1101-1108 [PMID: 36048724]
  13. Am J Prev Med. 2014 Jan;46(1):80-4 [PMID: 24355675]
  14. Acad Pediatr. 2022 May-Jun;22(4):573-580 [PMID: 35081470]
  15. Lancet Public Health. 2016 Nov;1(1):e8-e17 [PMID: 29253379]
  16. Cancer Epidemiol Biomarkers Prev. 2021 Jan;30(1):30-37 [PMID: 33082207]
  17. MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):109-113 [PMID: 33507893]
  18. Acad Pediatr. 2018 Sep - Oct;18(7):769-775 [PMID: 29842924]
  19. Cochrane Database Syst Rev. 2011;2011(4): [PMID: 25267916]
  20. Clin Infect Dis. 2018 Jan 18;66(3):339-345 [PMID: 29029053]
  21. N Engl J Med. 2020 Oct 1;383(14):1340-1348 [PMID: 32997908]
  22. Pediatrics. 2021 Jun;147(6): [PMID: 33941585]
  23. Lancet. 2021 Dec 4;398(10316):2084-2092 [PMID: 34741816]
  24. Lancet Oncol. 2020 Dec;21(12):1643-1652 [PMID: 33271093]
  25. Sex Transm Dis. 2017 Jun;44(6):365-370 [PMID: 28499288]
  26. Hum Vaccin Immunother. 2019;15(10):2460-2465 [PMID: 30862301]
  27. Pediatrics. 2022 Oct 1;150(4): [PMID: 36127315]
  28. Obstet Gynecol. 2020 Aug;136(2):e15-e21 [PMID: 32732766]
  29. Vaccines (Basel). 2021 Jul 01;9(7): [PMID: 34358132]
  30. Am J Health Promot. 2022 Sep;36(7):1152-1161 [PMID: 35442819]
  31. J Adolesc Health. 2014 Feb;54(2):190-6 [PMID: 24064282]
  32. J Pediatr. 2020 Feb;217:92-97 [PMID: 31757474]
  33. Pediatrics. 2019 Oct;144(4): [PMID: 31527175]
  34. Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):1981-1992 [PMID: 34426414]
  35. Prev Med. 2021 Oct;151:106596 [PMID: 34217415]
  36. MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702 [PMID: 31415491]
  37. Prev Med. 2016 Aug;89:327-333 [PMID: 26930513]
  38. Hum Vaccin Immunother. 2016 Jun 2;12(6):1454-68 [PMID: 26838681]
  39. MMWR Morb Mortal Wkly Rep. 2019 Aug 23;68(33):724-728 [PMID: 31437140]

MeSH Term

Humans
Female
Adult
Papillomavirus Vaccines
Papillomavirus Infections
Vaccination
Health Knowledge, Attitudes, Practice
Practice Patterns, Physicians'
Surveys and Questionnaires

Chemicals

Papillomavirus Vaccines

Word Cloud

Created with Highcharts 10.0.0HPVagesvaccinationrecommend9-10stronglyrecommendationvaccinepracticingfederallyqualifiedhealthcentersrecommendationsageCliniciansrecommendedpatients11-1213-1819-2627-45 yprovidersfamilymedicinespecialtyage:clinicianssafetynetsettingsClinicianremainscriticalfactorimprovinguptakesurveyedOctober2021July2022askedagedofferdiscusspatientinitiatesconversationDescriptivestatisticsassessedexactbinomiallogisticregressionanalysesutilizedexaminefactorsassociated9-10-y-oldRespondentsn = 148primarilyfemale85%30-3938%whitenon-Hispanic62%advancedpractice55%70%Northeast63%Strongvaried65%94%96%82%26%ComparedWomen'sHealth/OBGYNlesslikely = 03Approximatelytwo-thirdsseriesinitiationAdditionalresearchneededimproveyoungergroupssurveyiniationprovider

Similar Articles

Cited By